Going beyond the mAb: streamlining cell line development for Antibodies

Antibody drugs, such as monoclonal (mAb), bi- and tri-specific antibodies (BsAb and TsAbs), and antibody-drug conjugates (ADCs) are a cornerstone of biologic drug development. Production of mAb heavily relies on the robustness and efficiency of Cell Line Development (CLD). High-quality, high- producing clones that proceed through in CLD are then transferred to the Master Cell Bank (MCB), as candidates for scaling up during Process Development (PD). Ensuring an CLD workflow is critical to obtaining a high-quality product.

At the Life Sciences companies of Danaher, we develop innovative and integrated solutions in automation, analytics, and digital tools to improve the efficiency and productivity of mAb and other biotherapeutics.

• This fully-automatable analytical tool reduces mAb quantification toless than 15 minutes using a user-friendly workflow based on high-throughput detection of Immunoglobulin G (IgG).

• ValitaTiter enabling faster quality control and screening earlier in CLD .

Coupling these analytical tools with digital solutions like IDBS’s Polar Biopharma Lifecycle Management Software can speed up mAb development:

• The software curates data, facilitating process design, optimization and scale-up.

• Using the IDBS E-Workblook and Polar solutions can save over 14,000 hours of manual data handling time per year in a CLD department, enabling faster decision-making and shorter time-to-market for new antibodies.

The Life Sciences companies of Danaher address the challenges of CLD and CMC by developing solutions for our customers' workflows. With our coordinated portfolio of solutions, we are committed to providing streamlined and efficient CLD workflows for the development ofmonoclonal antibodies and other biotherapeutics.

Get in touch with us and talk to an expert to discover how we can help enable your next breakthrough.